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The development of hypertension in normotensive Wistar-Kyoto 
(WKY) and borderline hypertensive rats (BHR) was studied by 
inhibiting the synthesis of nitric oxide, an endothelial-derived 
relaxing factor. The BHR is genetically predisposed to developing 
hypertension in response to chronic exposure to environmental 
stress. After normalizing for initial systolic blood pressure (SBP), 
rats received drinking water that contained No-ni tro-L-arginine 
methyl ester (L-NAME) at concentrations of 0, 75, and 150 mg/L for 
three to four weeks. SBP, heart rate (HR), body weight (BW), and 
water consumption were measured weekly throughout L-NAME 
administration as well as during the subsequent two to three weeks 
following L-NAME withdrawal. L-NAME at either concentration 
produced progressively increasing hypertension in both the WKY and 
BHR rats by 21 days. The L-NAME-induced increase in SBP was 
reversed in the WKY when L-NAME was withdrawn but not in the 
BHR. Oral administration of L-NAME had no consistent effect on HR, 
BW, or water consumption although the administration of the 
150 mg/L concentration was in some instances fatal to BHRs. The 
irreversibility of the L-NAME-induced hypertension in the BHR 
illustrates the significance of genetic predisposition to the 
development of sustained hypertension. This method for induction 
of sustained hypertension in rats (BHR), which can be compared with 
norrnotensive litter mates, provides a useful hypertensive model. 
TABLES 
Tab le  
1.  Chart summarizing the experimental procedure 
. . . . . . . . . . . . . . . . . . . . . . .  for the WKY and BHR r a t s . .  
2. The BWs and SBPs of the WKY and BHR rats 
administered the 150 mg/L concentration of 
L-NAME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Figure 
1 .  Schematic diagram depicting the synthesis, release, 
and vasodilatory effect of EDRF . . . . . . . . . . . . . . . . . . . .  
2.  The chemical reaction resulting in the production of 
EmF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
3 .  The apparatus used for measuring SBP . . . . . . . . . . . . .  
4 .  The SBP measurements of the WKY rats in response 
. . . . . . . . .  to two different concentrations of L-NAME. 
5 .  The BWs of the WKY rats in response to two 
. . . . . . . . . . . . . . . .  different concentrations of L-NAME 
6. The water consumption of the WKY rats in response 
. . . . . . . . . .  to two different concentrations of L-NAME 
7 .  The water consumption of the WKY rats in response 
to two different concentrations of L-NAME as 
. . . . . . . . . . . . . . . . . . .  expressed per 100 grams of BW 
8. The concentration of L-NAME administered to the 
. . . . . . . . .  WKY rats as expressed per kilogram of B W .  
Page 
1 4  
Page 
9.  The HRs of the WKY rats in response to two 
different concentrations of L-NAME . . . . . . . . . . . . . . . .  
10 . The SBP measurements of the BHRs in response to 
L-NAME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 4 
. . . . . . . .  1 . The BWs of the BHRs in response to L-NAME 2 4 
1 2  . The HRs of the BHRs in response to L.NAME . . . . . . . . .  2 5 
1 3  . The SBP measurements of the WKY and BHR rats in 
response to 150 mg/L concentration of L-NAME . . . . .  2 5 
TABLE OF C 
Page 
ABBREVIATIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 
INTRODUCTION AND REVIEW OF THE LITERATURE . . . . . . . . . .  2 
MATERIALS AND METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  10  
RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 6  
DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 7  
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  CONCLUSION 3 4  
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  LlTERATURECIIED 3 5  
ABBREVIATIONS 
ACh 
ANS 
BHR 
BP 
BPM 
BW 
CNS 
m 
mw 
eNOS 
ET- 1 
HR 
NOS 
L-NAME 
L-NIO 
L-NMMA 
n 
NE 
nNOS 
NO 
NOS 
PRA 
SBP 
SEM 
SHR 
VSM 
VIJKY 
Acetylcholine 
Autonomic Nervous System 
Borderline Hypertensive Rat 
Blood Pressure 
Beats Per Minute 
Body Weight 
Central Nervous System 
Endothelial-derived Contracling Factor 
Endothelial-derived Relaxing Factor 
Endothelial Nitric Oxide Synthase 
Endothelin- 1 
Heart Rate 
Inducible Nitric Oxide Synthase 
N a-nitro-L-arginine methyl ester 
N-iminoethyl-L-ornithine 
Nw-monomethyl-L-arginine 
Sample Size 
Norepinephrine 
Neuronal Nitric Oxide S ynthase 
Nitric Oxide 
Nitric Oxide Synthase 
Plasma Renin Activity 
Systolic Blood Pressure 
Standard Error of the Mean 
Spontaneously Hypertensive Rats 
Vascular Smooth Muscle 
Wistar-Kyoto 
INTRODUCTION AND REVIEW OF THE LITERATURE 
The discovery of vascular endothelial secretory activity opened 
many new areas in hypertension research. The endothelium is a 
single-cell layer that lines all arteries and veins. It contributes to the 
tone of vascular smooth muscle (VSM) and mediates vasodilation in 
response to various stimuli including shear stress and the 
neurotransmitter, acetylcholine (ACh) (Furchgott and Zawadzki, 
1980). ACh binds to muscarinic cholinergic receptors located in the 
endothelial cell membrane which initiates the synthesis and release 
of the autocoid, nitric oxide (NO). Since cell membranes are 
permeable to small, gaseous molecules, NO readily diffuses into the 
adjacent VSM cells resulting in relaxation. This relaxation is 
achieved through the cGMP second messenger system that leads to 
activation of calcium pumps embedded in the plasma membrane and 
sarcoplasmic reticulum. The calcium pumps effectively lower the 
intracellular calcium concentration causing relaxation of VSM and 
dilation of the blood vessels (review by Shepard and Katusic, 1991). 
NO is an example of an endothelial-derived relaxing factor (EDRF). 
EDRFs are agents produced by the endothelium that stimulate VSM 
relaxation and subsequent dilation of the blood vessel. Landmark 
investigations (Ignarro et al., 1987) showed that NO is the primary 
EDRF regulating VSM. The endothelium also produces certain 
endothelial-derived contracting factors (EDCF) such as angiotensin 11, 
endothelin- 1 (ET- l) ,  prostaglandin Hz, and thromboxane A2. EDCFS 
act as vasoconstrictors, that is, they promote VSM contraction 
(review by Shepard and Katusic, 1991). The collective interaction of 
these endothelial-derived factors on VSM contributes toward the 
regulation of blood vessel tone. There is also an endothelial-derived 
hyperpolarizing factor which is still unidentified. 
NO is produced in the body by endothelial cells as well as by 
activated macrophages (Stuehr et al., 1989) and neutrophils (Wright 
et al., 1989). NO is synthesized by the enzyme, nitric oxide synthase 
(NOS), through the deamination of the amino acid, L-arginine 
(Forstermann et al., 1991). Currently, three different isoforms of NOS 
have been identified and studied in mammalian tissue (Forstermann 
et al., 1993; Nathan and Xie, 1994; Sessa, 1994). The isoforms 
contain unique amino acid sequences and their activities are 
influenced by the availability of cofactors. Ca2+, ATP, FAD, FMN, 
heme, NADPH, 0 2 ,  and tetrahydrobiopterin serve as cofactors 
necessary for NOS function. Endothelial NOS (eNOS) is associated with 
transient EDRF synthesis (Janssens et al., 1992; Lamas et al., 1992; 
Nishida et al., 1992; Sessa et al., 1992) and, therefore, is of particular 
relevance in this study. Calmodulin constitutes a regulatory subunit 
of the membrane bound eNOS enzyme complex which binds Ca2+ in 
the cytosol of the endothelial cell. eNOS is active at high intraceliufar 
Ga2+ levels. 
Other isoforms of NOS include neuronal NOS (nNOS) and inducible 
NOS (iNOS). nNOS is involved with signal transduction in central 
(Garthwaite et al., 1988) and peripheral neurons (Li and Rand, 1989) 
including those associated with the cardiovascular regulatory center 
(Forstermann et al., 1990) and perivascular nerves (Toda et al., 
1993). nNOS is similar to eNOS, in that it utilizes calmodulin (Bredt et 
al., 1991) and is involved with transient, Ca2+-dependent, NO 
production. iNOS, the third isoform of NOS, contains calmodulin (Cho 
et al., 1992) but is Ca2+-independent since it is active at normal 
intracellular Ca2+ levels. iNOS was first isolated from macrophages 
and can be located in most nucleated cells as part of the immune 
response to pathogens such as viruses (Karupiah et al., 1993; Nathan 
and Hibbs, 1991). iNOS, unlike eNOS and nNOS, participates in 
ongoing NO synthesis. 
After NO is synthesized, this small, hydrophobic molecule 
diffuses into neighboring cells. Due to its short half-life (5 to 
10 seconds), it acts only locally because it is converted to nitrates 
and nitrites by oxygen and water in the extracellular space (Wink et 
al., 1993). Once NO reaches the VSM cell cytosol, it reacts with iron 
in the active site of the enzyme guanylyl cyclase (Ignarro et al., 
1982). This stimulates the production of the intracellular mediator 
cGMP which greatly amplifies the signal (review by Lamb and Pugh, 
1992).  
The endothelium synthesizes NO incorporating the terminal 
guanidino nitrogen of L-arginine (Palmer et. al., 1988a). Synthesis of 
NO is an enantiomer-specific reaction and is inhibited in vitro by 
No-monomethyl-L-arginine (L-NMMA), but not its D-enantiomer 
(Palmer et al., 1988b). Other experiments showed NOS is also 
inhibited by N-iminoethyl-L-ornithine (L-NIO) and No-nitro-L- 
arginine methyl ester (L-NAME) in the adrenal gland (Palacios et al., 
1989) and brain (Knowles et al., 1990) (Figures 1 and 2). 
eNOS is inhibited by guanidino substituted analogues of 
L-arginine such as L-NMMA, L-NIO, and L-NAME. These analogues, 
both in vivo and in vitro, compete with L-arginine for binding sites 
Dialated 
Figure 1. Schematic diagram depicting th6 synthesis, release, md vattodilatory 
effect of EDRF. 
7' 
- - 
L- Arginine L-NAME 
Figure 2. a, The chemicaI reaction resulting in the production of EDRF. 
b, L-NAME, an analogue of L-arginine, inhibits this teaction. 
on eNOS (Rees et al., 1990), resulting in inhibition of NO synthesis. 
This Process is reversible over a short period of time through the 
addition of exogenous L-arginine or the removal of the L-arginine 
analogue from the biological system (Vallance et aI., 5989). Recent 
experiments have shown that increased duration of inhibitor 
exposure decreases the reversibility of the reaction (Olken and 
Marletta, 1993). 
Administration of L-NAME results in hypertension and serves as 
an excellent model for in vivo study because it is orally active 
(Gardiner et al., 1990). Aside from the action of L-NAME to 
competitively inhibit eNOS, other L-NAME actions may influence 
blood pressure (BP). L-NAME may limit NO production by acting as a 
muscarinic receptor antagonist (Buxton et al., 1993). By binding to a 
muscarinic receptor, L-NAME prevents the opening of the receptor 
operated calcium channel associated with this receptor and 
effectively eliminates ACh-mediated NO production. This secondary 
action of L-NAME should be considered in any experiment involving 
NOS inhibition via L-NAME. 
NOS inhibitors have also been shown to decrease plasma renin 
activity (PRA) in anesthetized (Johnson and Freeman, 1992; Sigmon 
et al., 1992) and unanesthetized rats (Navarro et al., 1994). In 
contrast to these studies, other researchers have reported that NOS 
inhibitors increase PRA (Dananberg et al., 1993; Oliveira et al., 1992; 
Salazar et al., 1992). Other effects of oral administration of NOS 
inhibitors include elevated catecholamine (Navarro et al., 1994; 
Zanchi et al., 1995) and ET-1 (Richard et al., 1995) levels and 
alterations in prostaglandin activity (Nakaike et al., 1995). These 
~ h ~ s i o l o g i c a l  changes may act synergistically or antagonistically in 
altering systolic blood pressure (SBP) and, therefore, should be taken 
into account in any experiment involving L-NAME-induced 
hypertension.  
When studying cardiovascular pathology, it is important to 
consider all factors involved with the onset of disease. Hypertension 
can be caused by various factors including stress, high salt intake, 
genetic predisposition, obesity, or vasoactive drugs. Early 
experiments with L-NAME-induced hypertension involved 
normotensive models such as the Brattleboro (Gardiner et al., 1990) 
and Wistar-Kyoto (WKY) rats (Rees et al., 1990). As stated earlier, 
this hypertension is reversible over a short period of time when 
L-NAME is removed. The Borderline Hypertensive Rat (BHR) 
represents an interesting model for hypertension research (Lawler et 
al., 1980). 
The BHR is the first generation offspring produced by mating 
female spontaneously hypertensive rats (SHR) with male WKY rats. 
Unlike the normotensive WKY rat, the BHR is genetically predisposed 
to developing hypertension. In the BHR, the onset of hypertension 
can be accelerated by environmental or physiological stimuli such as 
high salt diet. Further, unlike the WKY rat, the hypertension will 
persist even after removal of the high salt diet (Lawler et al., 1988) 
or other stressors (Lawler et al., 1981). By three months of age, male 
BHRs will have resting SBP measurements of approximately 
135 mmHg versus approximately 120 mmHg for the WKY (Morrow 
and Stratton, 1995). Consequently, one of the questions addressed 
by this study is to determine if L-NAME can produce hypertension 
in the BHR, and if so, will it persist following L-NAME withdrawal? 
A survey of the research literature in which L-NANIE has been 
used to induce hypertension provides no consensus on the 
appropriate concentration of L-NAME for oral administration. 
Reported concentrations in the drinking water range from 50 mg/L 
(Navarro et al., 1994) to 500 mg/L (Henrion et al., 1996). The 
inhibition of NO synthesis over extended periods of time results in 
premature death (8 to I 1  weeks in rats) due to organ damage (Arnal 
et al., 1992; Blot et al., 1994). This is surprising considering that the 
SHR can survive with similar SBP for up to 70 weeks (Kung and 
Luscher, 1995). A review of the literature has failed to demonstrate 
a consistent relationship between the amount of L-NAME ingested 
and the degree of eNOS inhibition. Consequently, a second question 
addressed by this study will be to determine an effective 
concentration of L-NAME for producing consistent and reliable 
hypertension.  
In summary, this study will examine the effects of NO inhibition 
on WMY and BHR rats. The subsequent reduced influence of NO on 
VSM in response to increasing L-NAME concentrations will be 
evaluated by measuring SBP. The reversibility of L-NAME-induced 
hypertension will be studied by replacing the L-NAME solution with 
normal tap water and continuing to monitor concomitant changes in 
SBP. 
MATERIALS AND METHODS 
The Wistar-Kyoto (WKY) rats were purchased from Taconic Farms, 
Germantown, New York while the Borderline Hypertensive Rats 
(BHRs) were bred from stock maintained within the Animal Care 
Facility at Drake University, Des Moines, Iowa. All rats were given at 
least a two day acclimatization period prior to any experimental 
manipulations. The rats were housed individually in standard 
stainless steel cages (with a length of 26 cm, width of 21 cm, and 
height of 21 cm) and exposed to a twelve hour lightldark cycle. All 
rats were fed HarladTeklad LM-485 sterilizable mouselrat diet 
7012.  
The drug used was NO-nitro-L-arginine methyl ester (L-NAME) 
which dissolved readily in tap water. It was obtained from Sigma 
Chemical Company, St. Louis, Missouri. Stocks of 10 L were made on 
a weekly basis from which the individual water bottles were filled. 
The final concentration was expressed as rng1L. 
L-NAME and WKY rats 
After weaning at four weeks of age, 27 male WKY rats were fed 
standard rat chow and tap water ad libitum for a four week period. 
At eight weeks of age, the body weight (BW) (g), heart rate (HR) 
(beatslminute (BPM)), and systolic blood pressure (SBP) (mmHg) of 
the WKY rats were measured. The HR and SBP were measured 
indirectly via tail cuff sphygmomanometry (Stratton et al., 1994) 
utilizing a programmed electro-sphygmomanometer and pneumatic 
pulse transducer (Narco Bio-Systems, Austin TX). Pfeffer et at. 
(1971) showed that SBPs determined by this method were consistent 
with direct blood pressure (BP) recordings of the carotid artery. 
To make these measurements, rats were restrained in the small 
animal study unit, were shielded from excessive visual stimulation, 
and were heated on a hot strip set at 40°C using the temperature 
control unit (Narco Bio-Systems, Austin TX). A minimum of 
15 minutes of acclimatization was allowed to assure adequate 
perfusion of the tail and to reduce stress induced changes in BP. An 
occluding cuff was placed around the base of each rat's tail with the 
bulb of the pneumatic pulse transducer positioned distal to the cuff 
to detect pulsatile flow changes in the caudal artery. The cuff was 
alternately inflated and deflated to 200 mmHg at a rate of 
20 mmHg/second. During acclimatization, the cuff was inflated and 
detlated several times. The sensitivity of the programmed electro- 
sphygmomanometer was uniformly maintained by setting the 
pressure amplitude at 4.6 and adjusting the sound-pulse amplitude 
over a range of 3 to 5. The pressure amplitude control determines 
the magnitude of graphical excursion in response to changes in the 
occluding cuff pressure (e.g. 100 mmHg = 3 cm of graphical 
excursion). The sound-pulse amplitude control regulates the 
sensitivity of the pneumatic pulse transducer. Pulsatile changes 
were recorded using the MacLabTM computer-aided data acquisition 
system running Chart software v.3.2 (AD Instruments, Castle Hill, 
NSW 2154, Australia) linked to a Macintosh IIci computer (Figure 3). 
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Figure 3 .  The apparatus used for measuring SBP. 
The mmerical average of three clearly measurable traces was 
recorded as each rat's SBP. This apparatus also measured HR and 
experimental values were obtained either before or after SBP 
determinations. 
After recording these measurements at eight weeks of age, the 
WKY rats were divided into three treatment groups matched by the 
initial SBP. This procedure involved arranging rats by magnitude of 
initial SBP and allocating every third rat to a different group. The 
order of allocation was reversed after placing the first 14 WKY rats 
in treatment groups to prevent the assignment of all rats with 
relatively low or high SBPs to the same group. All were fed standard 
rat chow ad libitum. Each group was allowed free access to tap water 
and the experimental groups received one of two different 
concentrations of L-NAME (75 mg/L or 150 mg/L) for the next four 
week period. L-NAME was then withdrawn and all WKY rats 
received tap water with no L-NAME for an additional two weeks. 
The water consumption of each animal was monitored throughout 
the experiment and was expressed as milliliters of water consumed 
per day and as milliliters of water consumed per 100 grams of BW. 
The amount of drug ingested was calculated and was expressed as 
milligrams of L-NAME per kilogram of BW. BW, HR, and SBP were 
measured weekly at approximately the same time (0700 to 1700). 
All rats were studied in the same order throughout the experiment 
and treatment groups were amalgamated to eliminate diurnal 
influences. Table 1 summarizes the entire protocol involving the 
WKY rats. 
Table 1. Chart summarizing the experimental procedure for the WKY and BHR 
rats. X indicates age of rat in weeks at time of experimental manipulation. 
House WKY and BHR s I x ~ X X X ~ X X X X ~  
Monitor WKY water I x X X X X X  
Record SBP, WR, and I x X X X X X X I  
BW of WKY and BHR s 
Match WKY and 
BHR s by initial SBP 
Add L-NAhE to water 
Add L-NAME to water 
Remove L-NAME from 
water of WKY rats 
L-NAME and BHRs 
A similar protocol was followed using 16 male BHRs. At 
approximately eight weeks of age, they were divided into two 
treatment groups matched by the initial SBP. The BHRs were housed 
individually and fed standard rat chow ad libitum throughout the 
experiment. One treatment group was administered 150 mg/L of 
L-NAME dissolved in tap water for three weeks while the other 
treatment group received drug free tap water. For three additional 
weeks, all BHRs received tap water with no drug. BW, HR, and SBP 
were measured weekly throughout the experiment. Table 1 
summarizes the entire protocol involving the BHRs. 
Statistical Analvsis 
The weekly values for each experimental group were plotted as 
the mean + standard error of the mean (SEM). The means were 
analyzed using ANOVA followed by Bonferroni's correction for 
multiple comparisons. Analyses were performed and graphs were 
designed using Abacus Concepts, StatView (Abacus Concepts, Inc., 
Berkeley, CA, 1992). 
RESULTS 
Systolic Blood Pressure of WKY Rats in Response to 75 mg/L and 
150 mg/L Concentrations of L-NAME in the Drinking Water. 
The Wistar-Kyoto (WKY) rats that ingested either concentration 
of NW-nitro-L-arginine methyl ester (L-NAME) showed significantly 
elevated systolic blood pressure (SBP) measurements after 14 days 
when compared to the control group (Figures 4 and 13, Table 2). 
Their SBP measurements continued to increase substantially the next 
two weeks with the highest SBP recordings for the group 
administered 150 mg/L of C-NAME. Statistically significant 
differences in SBP were observed between the 75 mg/L L-NAME and 
150 mg/L L-NAME groups over weeks three and four. The SBP 
measurements decreased to control levels in the L-NAME treatment 
groups over the final 14 days coinciding with the reintroduction of 
drug free tap water. The SBP recordings of the high and low 
L-NAME concentration groups remained significantly different from 
SBP readings of the control group during the fifth week despite 
diminishing SBP readings for both groups. At six weeks, there were 
no statistically significant differences in SBP 
Body We 
75 mg/L 
Water.  
ight and Water Consumption of WKY Rats in Response to 
and 150 mg/L Concentrations of L-NAME in the Drinking 
The body weights (BWs) of the WKY rats increased comparably 
in all three treatment groups irrespective of the presence or absence 
of L-NAME (Figure 5, Table 2). All three groups exhibited a similar 
growth pattern with mean BWs approximating the same values 
throughout the experiment. Over the 42 day period, the mean BW 
rose from 280 grams to 455 grams with an average daily gain of 
10.8 gramslday. Accompanying this normal rate of growth, water 
consumption increased by 8 mllday regardless of the concentration 
of L-NAME in the tap water (Figure 6). The administration of 
L-NAME via the tap water did not significantly alter water 
consumption in the WKY rats receiving L-NAME when compared to 
the control group. Water consumption decreased, however, on a 
milliliters of water consumed per 100 grams of BW basis as the 
animals matured (Figure 7). Further, the water consumption 
measurements indicate that the WKY rats administered 150 mg/L of 
L-NAME consistently received twice as much drug (16.9 mg 
L-NAME/ kg BW to 8.24 mg L-NAME/ kg BW) when compared to the 
WKY rats administered 75 mg/L of L-NAME (Figure 8). 
Heart Rate of WKY Rats in Response to 75 mg/L and 150 mg/L 
Concentrations of L-NAME in the Drinking Water. 
None of the treatment groups exhibited a consistent pattern of 
heart rate (HR) alteration (Figure 9). The HRs fluctuated over a 
broad range of values (329 beatdminute (BPM) to 376 BPM) 
throughout the experiment. During the sixth week, however, the 
WKY rats subjected to the high dose of L-NAME demonstrated a 
significant increase in HR. No other significant variations in HR were 
observed.  
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Figure 4. The SBP measurements of the WKY rats in response to two different 
concentrations of L-NAME. Control rats received no L-NAME. *(p<0.0167) 
150 mg/L and 75 mg/L different from control. #(p<0.0167) 150 mg/L different 
from 75 mg/L. 
450 
Body 4 0 0 -  
Weight 
(9) 350  - 
300  - 
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Figure 5. The BWs of the WKY rats in response to two different concentrations 
of L-NAME. 
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Figure 6. The water consumption of the WKY rats i n  response to two different 
concentrations of L-NAME. 
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Figure 7, The water consumption of the WKY rats in  response to two different 
concentrations of L-NAME as expressed per 100 grams of BW. 
Amountof 15.0 
Drug Ingested 1 3.0 
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Weeks 
Figure 8. The concentration of L-NAME administered to the WKY rats as 
expressed per kilogram of BW. *(p<0.0001) 150 mg/L different from 75 mg/L. 
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3 4 0  
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Weeks 
Figure 9. The HRs of the WKY rats in response to two different concentrations 
of L-NAME. *(p<0.0167) 150 mg/L different from control and 75 rng/L. 
Systolic Blood Pressure of BHRs in Response to 150 mglL 
Concentration of L-NAME in the Drinking Water. 
The SBP measurements of the Borderline Hypertensive Rats 
(BHRs) administered L-NAME were significantly higher than those of 
the control group throughout the experiment (Figures 10 and 13, 
Table 2). The BHRs receiving L-NAME exhibited marked 
hypertension after 21 days and remained hypertensive even after 
the withdrawal of L-NAME. Mean SBP measurements approximated 
170 mmHg after 28 days and subsequent measurements resulted in 
similar mean values during the withdrawal period. The SBP 
measurements of the control group increased gradually over the 
42 day period but values remained normotensive. 
One BHR administered 150 mg/L of L-NAME expired after 
21 days of treatment. Five BHRs were euthanized during the ensuing 
six days after exhibiting the following symptoms: lethargy, 
suppressed appetite, and loss of motor function in the pelvic 
appendages. Therefore, the sample size (n) was reduced to two over 
the final two weeks of the experiment for the affected treatment 
group. 
Body Weight of the BHRs in Response to 150 mg/L Concentration of 
L-NAME in the Drinking Water. 
The BWs of both treatment groups increased linearly over the 
first 14 days of the experiment (Figure 11, Table 2) with an average 
daily gain of 5.1 gramstday. The BWs of the BHRs receiving L-NAME 
decreased 33.9 grams during the third week of drug administration. 
Statistically significant differences in mean BW were recorded after 
21 days of L-NAME treatment. These differences remained 
significant during the last three weeks of the experiment despite 
evidence of compensatory weight gain after L-NAME withdrawal. 
Heart Rate of BHRs in Response to 150 mg/L Concentration of 
L-NAME in the Drinking Water. 
The mean HR of the control group was 376 BPM with minimal 
deviation from this value over the 42 day period (Figure 12). The 
BHRs administered 150 mglL of L-NAME showed no consistent 
pattern of HR alteration. HRs fluctuated over a wide range of values 
(331 BPM to 433 BPM) throughout the experiment. Significant 
differences in HR between the two treatment groups were recorded 
after seven and 28 days. 
180 
Systolic 
Blood I60 
Pressure 
1 4 0  
L-NAME Withdrawal 
Period Period 
Weeks 
Figure 10. The SBP measurements of the BHRs in response to L-NAME. Control 
rats received no L-NAME. *(PC 0.0024) 150 mg/L different from control. 
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Figure 11. The BWs of the BHRs in response to L-NAME. *fp<0.0262) 150 mg/L 
different from the control. 
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Figure 12. The HRs of the BHRs in response to L-NAME. *(p<0.0203) 150 mg/L 
different from the control. 
Systolic 
Blood 
Pressure 
(mmHg1 
Weeks 
Figure 13. The SBP measurements of the WKY and BHR rats in response to 
150 mg/L concentration of L-NAME. Control rats received no L-NAME. 
*(p<0.0024) BHR 150 mg/L different from BHR control. #(p<0.0167) WKY 
150 mg/L different from WKY control. +(p<0.0083) BHR 150 mg/L different 
from WKY 150 rng/L. 
Table 2. The BWs and SBPs of the WKY and BHR rats administered the 150 mg/L 
concentration of L-NAME. Control rats received no L-NAME. The values are 
means derived from measurements taken at the start of the experiment 
(week 0), after three to four weeks of L-NAME administration (week 4), and 
following the subsequent removal of L-NAME from the tap water (week 6). 
W KY Control 
WKY I50 mg/L 
BHR Control 
The sample size (n) described the number of rats per treatment group; BWs 
were measured in grams; SBP recordings were measured in mmHg. *(p<0.0167) 
WKY 150 mg/L different from WKY control. #(p<0.0262) BHR 150 mg/L 
different from BHR control. 
DISCUSSION 
Oral administration of NO-nitro-L-arginine methyl ester (L-NAME) 
induces consistent and reliable hypertension in both the Wjstar- 
Kyoto (WKY) and Borderline Hypertensive Rat (BHR) at a 
concentration of 150 mg/L (Figure 13, Table 2). The observed 
increases in the systolic blood pressure (SBP) of WKY rats after the 
oral administration of L-NAME agree with the findings of other 
studies using similar concentrations of L-NAME (Navarro et al., 2994; 
Qiu et al., 1994). The value of a BHR model for hypertension is that 
the blood pressure (BP) remains elevated for several months after an 
environmental stress is withdrawn. Thus, the hypertensive BHR can 
be compared to normotensive litter mates long after the 
hypertensive stimulus is withdrawn. The use of L-NAME constitutes 
an attractive method for developing hypertension in the BHR in 
comparison to current, commonly used techniques. A frequently 
used procedure for elevating SBP in the BHR consists of prolonged 
exposure to a noxious environmental stimulus such as an electric 
shock (Lawler et al., 1980; Lawler et al., 1981). Air jet noise is 
another environmental stimulus used to induce hypertension in the 
BHR (Fisher and Tucker, 1991). These procedures require extended 
conditioning periods and are often labor intensive. Other protocols 
utilize a physiological stimulus such as a high salt diet for 
hypertension development (Lawler et al., 1988). This protocol 
introduces the added physiological complications of hypernatremia 
and natriuresis. L-NAME, however, produces hypertension by acting 
as a pharmacological stimulus. L-NANIE-induced hypertension 
simplifies experimental design by providing an alternative to 
exposing BHRs to noxious environmental or physiological stimuli. 
L-NAME elevates SBP through a myriad of physiological 
mechanisms involved with BP modulation. As a competitive 
inhibitor of endothelial nitric oxide synthase (eNOS), L-NAME blocks 
the synthesis of the autocoid nitric oxide (NO), an endothelial-derived 
relaxing factor (EDRF). The decrease in relaxing factor results in an 
increased peripheral resistance and a concomitant rise in SEIP. This is 
believed to be the primary mechanism of hypertension employed by 
L-NAME (Bank et al., 1994). Recent evidence indicates that L-NAME 
may also act as a muscarinic receptor antagonist further enhancing 
its effect as a hypertensive agent by competitively inhibiting 
acetylcholine (ACh)-mediated vasodilation (Buxton et al., 1993). 
Although not statistically significant, the recorded HRs of the WKY 
and BHR rats in this study (Figures 9 and 12) revealed a trend 
toward a drop in HR for all treatment groups except the WKY and 
BHR controls. The observed decrease in HR may be compensatory 
and certainly runs counter to any antimuscarinic chemotropic actions 
due to the oral consumption of L-NAME. This trend continued 
throughout the period of L-NAME administration in both the WKY 
and BHR rats until L-NAME withdrawal. The WKY and BHR rats 
administered 150 mg/L of L-NAME exhibited an increase in HR 
following the removal of L-NAME from the drinking water. 
Since Ignarro et al. (1987) first described NO as the EDRF produced 
and released from arteries and veins, many additional paracrine 
functions for NO have been proposed. Consequently, L-NAME, as an 
orally active agent, may alter other cellular activities regulated by 
this ubiquitous chemical messenger. L-NAME competitively inhibits 
all three isoforms of nitric oxide synthase (NOS) (Knowles et al., 1990; 
Palacios et al., 1989; Rees et al., 1990). Inhibition of inducible NOS 
(iNOS) may disrupt the immune response to pathogens in most 
nucleated mammalian cells including macrophages (Karupiah et al., 
1993; Nathan and Hibbs, 1991). iNOS catalyzes the production of NO 
for subsequent use as a cytotoxin against pathogens. Inhibition of 
neuronal NOS (nNOS) may prevent NO from acting as a signaling 
molecule in the brain (Garthwaite et al. 1988) or as a 
neurotransmitter in peripheral nerves (Li and Rand, 1989). These 
findings suggest that L-NAME-induced hypertension could involve 
alterations in the BP regulating activities of the central nervous 
system (CNS) and autonomic nervous system (ANS). The existence 
of nNOS activity within the medulla oblongata (Forstermann et al., 
1990) potentially implicates an additional hypertensive effect of 
L-NAME involving nNOS inhibition within the cardiovascular 
regulatory center. Toda et al. (1993) postulates that L-NAME inhibits 
nitroxidergic nerve activity by inhibiting the production of NO. 
"Nitroxidergic" is a term used to describe nerves that use NO as a 
neurotransmitter in signal transduction. Many of these nitroxidergic 
nerves are perivascular and cause vasodilation of blood vessels upon 
activation (Toda and Okamura, 1991). The significance of nNOS 
inhibition with respect to VSM tone requires further investigation. 
L-NAME further influences SBP by regulating plasma renin 
activity (PRA). High levels of cGMP in juxtaglomerular cells result in 
the inhibition of renin release. As described previously, NO 
stimulates cGMP production by activating guanylyl cyclase. 
Therefore, inhibition of NO synthesis enhances renin release (Zanchi 
et al., 1995) by decreasing cGMP levels in juxtaglomerular cells 
(Sigmon et al., 1992). Navarro et al. (1994) have postulated that 
limiting NO production through the administration of L-NAME, for 
example, may actually attenuate pressure-dependent renin release. 
Under normal physiological conditions, elevations in blood pressure 
lead to reductions in PRA. Further, NO may be the paracrine 
mediator that inversely links renal perfusion pressure with the 
stimulation of renin release (Knoblich et al., 1996). Based on these 
two observations, NOS inhibition would lead to decreased renin 
release. Low circulating renin levels lower SBP by lessening the 
vasoconstrictive activity of the renin-angiotensin system. These 
physiological mechanisms would actually ameliorate the L-NAME- 
induced hypertension. 
An additional mechanism of L-NAME-induced hypertension may 
involve elevations in circulating catecholamines. Oral administration 
of L-NAME increased plasma levels of epinephrine and 
norepinephrine (NE) in rats (Navarro et al., 1994; Zanchi et al., 1995). 
Of particular interest was the finding by Navarro et al. (1994) that 
only rats receiving a high concentration of L-NAME (300 mg/L) 
exhibited marked elevations in circulating catecholamines. This was 
contrary to other experimental groups receiving lower concentrations 
of L-NAME. By raising catecholamine levels, L-NAME indirectly 
enhances its hypertensive effect via stimulation of alpha adrenergic 
receptors. 
In this study, L-NAME-induced hypertension was reversible in 
the WKY rat when animals received water without L-NAME (Figure 
13 and Table 2). Thus, the hypertensive activity of L-NAME was 
transient and SBP measurements returned to basal levels within 
14 days. In contrast, the L-NAME-induced hypertension was 
irreversible in the BHR even after L-NAME withdrawal. These 
results emphasize the significance of genetic predisposition in the 
development of sustained hypertension. 
Folkow (1982) hypothesized that the susceptibility of an organism 
to developing hypertension in response to an environmental stressor 
is determined by the organism's genetic bias to high arterial 
pressure. This genetic bias potentially affects a multitude of BP 
regulating mechanisms but published reports indicate that CNS, 
kidneys, and ANS play critical roles (review by Sanders and Lawler, 
1992). The amygdala, hypothalamus, pons, and medulla oblongata 
contain high densities of alpha2 adrenergic receptors (Moore and 
Bloom, 1979). Alpha2 adrenergic agonists suppress the activation of 
the ANS (Charney et al., 1983). An impairment in alphaz adrenergic 
receptors in the BHR may result in an overstimulation of the ANS and 
a concomitant hypersecretion of catecholamines from the adrenal 
medulla in response to an acute stressor (Hubbard et al., 1986b). 
This impairment may involve altering ligand binding to alpha2 
receptors in the CNS. Lundin and Thoren (1982) described the 
antinatriuretic effect air jet exposure had on SHRs but not WKY rats 
and, therefore, implicated that the genetic predisposition of the BHR 
towards hypertension may involve alterations in renal function. 
Exaggerated circulating plasma NE levels have been demonstrated in 
the BHR in response to tail-shock stress thus involving the ANS in the 
onset of hypertension (Hubbard et al., 1986a). All of these 
physiological responses increase SBP and may predispose the BHR to 
developing hypertension. 
Future experimentation with BHRs should employ lower 
concentrations of L-NAME. L-NAME induced concentration- 
dependent hypertension in the WKY rats as indicated by Figure 4. 
The concentrations of L-NAME used in this study (75 and 150 mg/L) 
were similar to those used by Gardiner et al. (1990) (100 mg/L) 
when L-NAME was first described as being orally active. Findings in 
this study indicate that administering higher levels of L-NAME 
causes a malignant form of hypertension. BHRs receiving 150 mg/L 
of L-NAME may exhibit decreased BW, lethargy, and stroke as 
evidenced by loss of motor function. Counter to these observations, 
Zanchi et al. (1995) induced hypertension in male Wistar rats by 
administering 400 mg/L of L-NAME over a six week period and only 
observed a small decrease in BW (without any reported evidence of 
stroke). A concentration of 75 mg/L, while still provoking significant 
elevations in SBP in WKY rats, may decrease the incidence of stroke 
observed in BHRs administered 150 mg/L of L-NAME. 
By using a lower concentration of L-NAME, it may be possible to 
determine the specific mechanisms of action of L-NAME in elevating 
SBP (besides eNOS inhibition). One possible approach would involve 
contracting blood vessel rings from the superior mesenteric artery 
(as a model for resistance blood vessels) in a defined medium 
containing L-NAME in a physiological concentration similar to levels 
achieved during oral administration. Adrenergic agonists would be 
of special interest since the ANS appears to play a major role in 
L-NAME-induced hypertension (review by Sanders and Lawler, 
1992). 
Experimental protocoIs with a prolonged period of L-NAME 
withdrawal may prove advantageous. This study demonstrated that 
L-NAME-induced hypertension in the BHR is not reversed by 
removal of L-NAME from the tap water. This observation was based 
on three weeks of SBP measurements following L-NAME withdrawal 
and does not necessarily predict the long term effect of L-NAME on 
sustained hypertension in the BHR. 
Oral administration of L-NAME to the BHR serves as a useful 
model for studying sustained hypertension. Physicians and 
researchers have long suspected that genetic predisposition plays a 
key role in the onset of primary hypertension. Experimentation with 
the BHR allows researchers to focus efforts on the genetic component 
of hypertension and further delineate the underlying mechanisms of 
vascular pathology. 
CONCLUSION 
This study demonstrates that oral administration of No-ni tro-L- 
arginine methyl ester (L-NAME) via tap water can induce 
hypertension in the Wistar-Kyoto (WKY) rat at concentrations of 
75 and 150 mg/L and in the Borderline Hypertensive Rat (BHR) at a 
concentration of 150 mgIL. L-NAME-induced hypertension is 
reversible in the WKY but not the BHR rat when L-NAME is 
withdrawn from the tap water illustrating the significance of genetic 
predisposition in the development of sustained hypertension. The 
75 mg/L concentration can produce significant hypertension in three 
weeks without additional pathological complications. Since L-NAME 
is orally active, this technique is not labor intensive. This method of 
induction of sustained hypertension in rats (BHR), which can be 
compared with normotensive litter mates, provides a useful 
hypertensive model. 
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